Remove Cardiac Function Remove Heart Failure Remove Pharmacology
article thumbnail

Circulating neutrophil?related proteins associate with incident heart failure and cardiac dysfunction: The ARIC study

European Journal of Heart Failure

Associations of colchicine-related plasma proteins, incident heart failure (HF) and cardiac structure and function. HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction.

article thumbnail

Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function

Circulation

BACKGROUND:Cardiac metabolic dysfunction is a hallmark of heart failure (HF). Estrogen-related receptors ERRα and ERRγ are essential regulators of cardiac metabolism. We investigated the effect of ERR agonist on cardiac function in a pressure overload–induced HF model in vivo. Circulation, Ahead of Print.

article thumbnail

USF Health Heart Institute Doctors Are Upbeat about Cardiac Regeneration

DAIC

Since mitochondrial protein synthesis is critical to its structure, as well as normal cardiac function, the authors focused much of their study on how alteration of the mitochondrial protein balance affects heart health.

article thumbnail

Abstract 4140419: Targeting Cardiac Fibrosis with Chimeric Antigen Receptor Neutrophils from Human Pluripotent Stem Cells

Circulation

Cardiac fibrosis is a pathological hallmark of almost all forms of heart disease, characterized by excessive deposition of extracellular matrix (ECM) proteins by activated fibroblasts, leading to cardiomyocyte hypertrophy, arrhythmias, and heart failure.

article thumbnail

Canagliflozin mediates mitophagy through the AMPK/PINK1/PARKIN pathway to alleviate isoprenaline-induced cardiac remodelling

Journal of Cardiovascular Pharmacology

Heart failure has always been a prevalent, disabling, and potentially life-threatening disease. For the treatment of heart failure, controlling cardiac remodeling is very important. Heart failure has always been a prevalent, disabling, and potentially life-threatening disease.

article thumbnail

The combination of valsartan and spironolactone mitigated mitral regurgitation induced cardiac dysfunction in a novel rat model

Journal of Cardiovascular Pharmacology

Although the mineralocorticoid-receptor antagonist spironolactone, in conjunction with renin-angiotensin system (RAS) inhibitors, has been shown to reduce mortality in patients with heart failure with reduced ejection fraction (HFrEF), its efficacy in managing degenerative MR is uncertain.